{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T01:48:17Z","timestamp":1781920097709,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-024-05741-y","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T05:02:49Z","timestamp":1729659769000},"page":"3151-3156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Difficult-to-treat Takayasu arteritis: a case-based review"],"prefix":"10.1007","volume":"44","author":[{"given":"Nabil","family":"Belfeki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouha","family":"Ghriss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Guedec-Ghelfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Kammoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemie","family":"Abisror","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsene","family":"Mekinian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"5741_CR1","doi-asserted-by":"crossref","unstructured":"Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F et al (2013) 2012 revised international chapel Hill Consensus Conference nomenclature of Vasculitides. Arthritis Rheum 65:1\u201311","DOI":"10.1002\/art.37715"},{"key":"5741_CR2","first-page":"e197","volume":"46","author":"F Onen","year":"2017","unstructured":"Onen F, Akkoc N (2017) Epidemiology of Takayasu arteritis. Presse Medicale Paris Fr 1983 46:e197\u2013203","journal-title":"Presse Medicale Paris Fr 1983"},{"key":"5741_CR3","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1093\/rheumatology\/kead161","volume":"62","author":"A Tomelleri","year":"2023","unstructured":"Tomelleri A, Padoan R, Kavadichanda CG, Jose A, Singh K, Iorio L et al (2023) Validation of the 2022 American College of Rheumatology\/EULAR classification criteria for Takayasu arteritis. Rheumatol Oxf Engl 62:3427\u20133432","journal-title":"Rheumatol Oxf Engl"},{"key":"5741_CR4","doi-asserted-by":"publisher","first-page":"e001003","DOI":"10.1136\/rmdopen-2019-001003","volume":"5","author":"S Monti","year":"2019","unstructured":"Monti S, \u00c1gueda AF, Luqmani RA, Buttgereit F, Cid M, Dejaco C et al (2019) Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. RMD Open 5:e001003","journal-title":"RMD Open"},{"key":"5741_CR5","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1136\/annrheumdis-2017-211878","volume":"77","author":"Y Nakaoka","year":"2018","unstructured":"Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S et al (2018) Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis 77:348\u2013354","journal-title":"Ann Rheum Dis"},{"key":"5741_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejim.2024.04.004","volume":"126","author":"X Sun","year":"2024","unstructured":"Sun X, Fang C, Jin S, Li J, Yang Y, Zeng X et al (2024) Serum IL-6 level trajectory for predicting the effectiveness and safety of tocilizumab in the treatment of refractory Takayasu arteritis. Eur J Intern Med 126:77\u201382","journal-title":"Eur J Intern Med"},{"key":"5741_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1515\/rir-2024-0002","volume":"5","author":"X Tian","year":"2024","unstructured":"Tian X, Zeng X (2024) Chinese guideline for the diagnosis and treatment of Takayasu\u2019s arteritis (2023). Rheumatol Immunol Res 5:5\u201326","journal-title":"Rheumatol Immunol Res"},{"key":"5741_CR8","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1136\/ard-2022-223482","volume":"81","author":"PC Grayson","year":"2022","unstructured":"Grayson PC, Ponte C, Suppiah R, Robson JC, Gribbons KB, Judge A et al (2022) 2022 American College of Rheumatology\/EULAR classification criteria for Takayasu arteritis. Ann Rheum Dis 81:1654\u20131660","journal-title":"Ann Rheum Dis"},{"key":"5741_CR9","doi-asserted-by":"publisher","first-page":"356","DOI":"10.31138\/mjr.230929.su","volume":"34","author":"P MV","year":"2023","unstructured":"MV P, Maikap D, Padhan P (2023) Successful use of Tofacitinib in Refractory Takayasu Arteritis: a Case Series. Mediterr J Rheumatol 34:356\u2013362","journal-title":"Mediterr J Rheumatol"},{"key":"5741_CR10","doi-asserted-by":"publisher","first-page":"e003985","DOI":"10.1136\/rmdopen-2023-003985","volume":"10","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, Fang C, Wang L, Li J, Yang Y, Zhang L et al (2024) Baricitinib for refractory Takayasu arteritis: a prospective cohort study in a tertiary referral centre. RMD Open 10:e003985","journal-title":"RMD Open"},{"key":"5741_CR11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1536\/ihj.23-195","volume":"64","author":"C As","year":"2023","unstructured":"As C, Danda D (2023) Current diagnosis and management of Takayasu Arteritis. Int Heart J 64:519\u2013534","journal-title":"Int Heart J"},{"key":"5741_CR12","doi-asserted-by":"crossref","unstructured":"Bhandari S, Butt SRR, Ishfaq A, Attaallah MH, Ekhator C, Halappa Nagaraj R et al (2023) Pathophysiology, diagnosis, and management of Takayasu Arteritis: a review of current advances. Cureus 2915:e42667","DOI":"10.7759\/cureus.42667"},{"key":"5741_CR13","doi-asserted-by":"crossref","unstructured":"Arita Y, Ishibashi T, Nakaoka Y (2023) Current immunosuppressive treatment for Takayasu Arteritis. Circ J off J Jpn Circ Soc 88(10)","DOI":"10.1253\/circj.CJ-23-0780"},{"key":"5741_CR14","first-page":"456","volume":"60","author":"P Moisii","year":"2024","unstructured":"Moisii P, Jari I, Naum AG, Butcovan D, Tinica G (2024) Takayasu\u2019s arteritis: a Special Case Report and Review of the literature. Med (Mex 60:456","journal-title":"Med (Mex"},{"key":"5741_CR15","first-page":"16606","volume":"134","author":"I \u0141o\u0144","year":"2024","unstructured":"\u0141o\u0144 I, Le\u015bnowolski \u0141, Janiec I, Januszewicz M, Sobieraj P, Lewandowski J (2024) Severe course of type IV Takayasu disease during treatment with etanercept. Pol Arch Intern Med 134:16606","journal-title":"Pol Arch Intern Med"},{"key":"5741_CR16","doi-asserted-by":"publisher","first-page":"e002830","DOI":"10.1136\/rmdopen-2022-002830","volume":"9","author":"A Mekinian","year":"2023","unstructured":"Mekinian A, Biard L, Lorenzo D, Novikov PI, Salvarani C, Espitia O et al (2023) Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study. RMD Open 9:e002830","journal-title":"RMD Open"},{"key":"5741_CR17","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13075-020-02311-y","volume":"22","author":"A Mekinian","year":"2020","unstructured":"Mekinian A, Saadoun D, Vicaut E, Thietart S, Lioger B, Jego P et al (2020) Tocilizumab in treatment-na\u00efve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial. Arthritis Res Ther 22:218","journal-title":"Arthritis Res Ther"},{"key":"5741_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","volume":"79","author":"B Hellmich","year":"2020","unstructured":"Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E et al (2020) 2018 update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 79:19\u201330","journal-title":"Ann Rheum Dis"},{"key":"5741_CR19","doi-asserted-by":"publisher","first-page":"e003992","DOI":"10.1136\/rmdopen-2023-003992","volume":"10","author":"F Peron Filho","year":"2024","unstructured":"Peron Filho F, Moreira A, de Janes S, de Souza ALF (2024) Effectiveness and safety of adalimumab compared with leflunomide in patients with Takayasu arteritis: a retrospective cohort study. RMD Open 10:e003992","journal-title":"RMD Open"},{"key":"5741_CR20","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1093\/rheumatology\/keab635","volume":"61","author":"A Mekinian","year":"2022","unstructured":"Mekinian A, Biard L, Dagna L, Novikov P, Salvarani C, Espitia O et al (2022) Efficacy and safety of TNF-\u03b1 antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients. Rheumatol Oxf Engl 61:1376\u20131384","journal-title":"Rheumatol Oxf Engl"},{"key":"5741_CR21","first-page":"1793","volume":"30","author":"AK Valsakumar","year":"2003","unstructured":"Valsakumar AK, Valappil UC, Jorapur V, Garg N, Nityanand S, Sinha N (2003) Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu\u2019s arteritis. J Rheumatol 30:1793\u20131798","journal-title":"J Rheumatol"},{"key":"5741_CR22","first-page":"163","volume":"70","author":"F Baert","year":"2007","unstructured":"Baert F, De Vos M, Louis E, Vermeire S, Belgian IBD, Research Group (2007) Immunogenicity of infliximab: how to handle the problem? Acta Gastro-Enterol. Belg 70:163\u2013170","journal-title":"Belg"},{"key":"5741_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1146\/annurev-med-060622-100940","volume":"75","author":"MS Kaymakci","year":"2024","unstructured":"Kaymakci MS, Warrington KJ, Kermani TA (2024) New therapeutic approaches to large-vessel vasculitis. Annu Rev Med 75:427\u2013442","journal-title":"Annu Rev Med"},{"key":"5741_CR24","doi-asserted-by":"publisher","first-page":"282","DOI":"10.31138\/mjr.20230929.taa","volume":"34","author":"T Dimitroulas","year":"2023","unstructured":"Dimitroulas T (2023) Tofacitinib as a promising therapeutic option in refractory autoimmune-mediated vascular and sclera inflammation. Mediterr J Rheumatol 34:282\u2013283","journal-title":"Mediterr J Rheumatol"},{"key":"5741_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1136\/annrheumdis-2021-220832","volume":"81","author":"X Kong","year":"2022","unstructured":"Kong X, Sun Y, Dai X, Wang L, Ji Z, Chen H et al (2022) Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study. Ann Rheum Dis 81:117\u2013123","journal-title":"Ann Rheum Dis"},{"key":"5741_CR26","doi-asserted-by":"publisher","first-page":"152018","DOI":"10.1016\/j.semarthrit.2022.152018","volume":"55","author":"J Wang","year":"2022","unstructured":"Wang J, Dai X, Ma L, Wu S, Jin X, Ji Z et al (2022) Efficacy and safety of tofacitinib versus leflunomide with glucocorticoids treatment in Takayasu arteritis: a prospective study. Semin Arthritis Rheum 55:152018","journal-title":"Semin Arthritis Rheum"},{"key":"5741_CR27","doi-asserted-by":"publisher","first-page":"105658","DOI":"10.1016\/j.jbspin.2023.105658","volume":"91","author":"A Mekinian","year":"2024","unstructured":"Mekinian A, No\u00e9 L, Salvarani C, Dagna L, Espitia O, Biard L et al (2024) Effectiveness and safety of Rituximab in Takayasu arteritis: a multicenter retrospective study. Joint Bone Spine 91:105658","journal-title":"Joint Bone Spine"},{"key":"5741_CR28","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s10067-014-2506-5","volume":"33","author":"E Caltran","year":"2014","unstructured":"Caltran E, Di Colo G, Ghigliotti G, Capecchi R, Catarsi E, Puxeddu I et al (2014) Two Takayasu arteritis patients successfully treated with rituximab. Clin Rheumatol 33:1183\u20131184","journal-title":"Clin Rheumatol"},{"key":"5741_CR29","first-page":"406963","volume":"2012","author":"D Ernst","year":"2012","unstructured":"Ernst D, Greer M, Stoll M, Meyer-Olson D, Schmidt RE, Witte T (2012) Remission achieved in Refractory Advanced Takayasu Arteritis using Rituximab. Case Rep. Rheumatol 2012:406963","journal-title":"Rheumatol"},{"key":"5741_CR30","doi-asserted-by":"publisher","first-page":"rkaa082","DOI":"10.1093\/rap\/rkaa082","volume":"5","author":"SJ Saur","year":"2021","unstructured":"Saur SJ, Horger M, Henes J (2021) Successful treatment with the IL12\/IL23 antagonist ustekinumab in a patient with refractory Takayasu arteritis. Rheumatol Adv Pract 5:rkaa082","journal-title":"Rheumatol Adv Pract"},{"key":"5741_CR31","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1080\/14397595.2020.1800560","volume":"31","author":"Y Gon","year":"2021","unstructured":"Gon Y, Yoshifuji H, Nakajima T, Murakami K, Nakashima R, Ohmura K et al (2021) Long-term outcomes of refractory Takayasu arteritis patients treated with biologics including ustekinumab. Mod Rheumatol 31:678\u2013683","journal-title":"Mod Rheumatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05741-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-024-05741-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05741-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T16:06:31Z","timestamp":1733328391000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-024-05741-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":31,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5741"],"URL":"https:\/\/doi.org\/10.1007\/s00296-024-05741-y","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]},"assertion":[{"value":"2 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors obtained written consent from the patient for their photographs and medical information to be published in print and online. Patient consent form is retained by the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Authors declare that they have no conflict of interest. We are interested in publishing our work in an open access format. The draft did not have any industry support.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}